Page 98 - 《中国药房》2022年10期

·药物与临床·

地氯雷他定治疗荨麻疹的临床综合评价 Δ

刘 璐 ，甄路路 ，任美娟 ，李 蕊 ，刘 畅 ，闫美兴 （1.青岛大学附属妇女儿童医院药学部，山东 青岛
1
2
2
1 #
1＊
2
266034；2.中国海洋大学医药学院，山东 青岛 266000）
中图分类号 R986；R751.05 文献标志码 A 文章编号 1001-0408（2022）10-1240-07
DOI 10.6039/j.issn.1001-0408.2022.10.14
摘 要 目的 多维度评价地氯雷他定治疗荨麻疹的临床综合价值。方法 运用文献调查法和专家调研法初步确定基于安全性、有
效性、经济性、适宜性、创新性、可及性6个维度的临床综合评价指标；采用德尔菲法和层次分析法对评价指标体系的核心内容进
行评价和筛选；采用Likert 5级评分法对指标的重要性进行赋值；借助系统评价、药品说明书、专家指南/共识、药品不良反应监测
报告等，根据临床综合评价指标体系收集各来源证据并进行定性及定量整合分析；由专家根据地氯雷他定各维度临床综合评价证
据进行评分，结合临床综合评价指标体系权重计算得到地氯雷他定三级指标的临床综合评价得分，各指标得分累加即为药品的临
床综合评价总分，并与氯雷他定进行比较。结果 本研究成功构建地氯雷他定治疗荨麻疹的临床综合评价指标体系，包括6个一级
指标、13个二级指标、30个三级指标。地氯雷他定的临床综合评价总分为93.63分，氯雷他定为70.91分。结论 地氯雷他定的临床
综合价值高于氯雷他定，可为医疗机构临床合理用药、用药目录遴选及国家药物政策完善提供参考依据。
关键词 地氯雷他定；氯雷他定；荨麻疹；临床综合评价；德尔菲法；层次分析法

Clinical comprehensive evaluation of desloratadine in the treatment of urticaria
LIU Lu ，ZHEN Lulu ，REN Meijuan ，LI Rui ，LIU Chang ，YAN Meixing（1. Dept. of Pharmacy，Qingdao
2
1
1
1
2
2
Women and Children’s Hospital of Qingdao University，Shandong Qingdao 266034，China；2. School of
Medicine and Pharmacy，Ocean University of China，Shandong Qingdao 266000，China）
ABSTRACT OBJECTIVE To evaluate the clinical comprehensive value of desloratadine in the treatment of urticaria. METHODS
The clinical comprehensive evaluation index system based on six dimensions such as safety，effectiveness，economy，suitability，
innovation and accessibility were preliminarily determined by using the methods of literature investigation and expert investigation；
the core contents of the evaluation index system were evaluated and screened by Delphi method and analytic hierarchy process；the
importance of the index was assigned by Likert 5-level scoring method；the evidence from various sources were collected and
qualitative and quantitative integration analysis were conducted according to the clinical comprehensive evaluation index system
with the help of system evaluation，drug instructions，expert guidelines/consensus，adverse drug reaction monitoring report，etc；
the experts scored its clinical comprehensive value according to the clinical comprehensive evaluation evidence of each dimension
of desloratadine，combined with the weight of the clinical comprehensive evaluation index system，the clinical comprehensive
evaluation score of the tertiary indexes of desloratadine were calculated. The total clinical comprehensive evaluation score was
obtained by accumulating the scores of each index，and compared with loratadine. RESULTS This study successfully constructed
the clinical comprehensive evaluation index system of desloratadine in the treatment of urticaria，including 6 primary indexes，13
secondary indexes and 30 tertiary indexes. The total clinical comprehensive evaluation score of desloratadine was 93.63 and that of
loratadine was 70.91. CONCLUSIONS The clinical comprehensive value of desloratadine is higher than that of loratadine，which
can provide a reference basis for clinical rational drug use in medical institutions，selection of drug use catalogue and improvement
of national drug policy.
KEYWORDS desloratadine；loratadine；urticaria；clinical comprehensive evaluation；Delphi method；analytic hierarchy process

[2]
荨麻疹是临床常见的过敏性疾病，全球发病率约为 可出现呼吸系统、循环系统和消化系统症状 。荨麻疹
20％，年病发率约为 1.4％ ，其主要临床表现为大小不 容易反复发作，病情迁延不愈，严重降低患者的生活质
[1]
等的风团伴瘙痒，也可伴血管性水肿或刺痛感，严重时 量，给患者家庭甚至社会造成巨大的经济负担 [3－4] 。目
Δ 基金项目：山东省药学会科研项目（No.SDSYXH-KY-202105） 前，国内外专家指南/共识均推荐第 2 代非镇静 H1 抗组
＊主管药师，博士。研究方向：儿童药品临床综合评价。电话： [1 － 5]
胺药作为治疗荨麻疹的一线药物 。地氯雷他定
0532-68661375。E-mail：liulu208@163.com
（desloratadine，又名“地洛他定”）是与组胺 H1 受体亲和
# 通信作者：主任药师，硕士生导师。研究方向：医院药事管理、
[6]
临床药学。电话：0532-68661278。E-mail：meixing@163.com 力较高的新型第 2 代抗组胺药 ，是氯雷他定（lorata-

·1240 · China Pharmacy 2022 Vol. 33 No. 10 中国药房 2022年第33卷第10期